Altimmune, Inc. (NASDAQ:ALT) Stake Lifted by Bellevue Group AG

Bellevue Group AG raised its stake in Altimmune, Inc. (NASDAQ:ALT - Free Report) by 43.9% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 863,660 shares of the company's stock after purchasing an additional 263,660 shares during the quarter. Bellevue Group AG owned about 1.22% of Altimmune worth $5,303,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in ALT. Dimensional Fund Advisors LP boosted its holdings in Altimmune by 142.9% in the second quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company's stock valued at $3,791,000 after acquiring an additional 335,444 shares during the last quarter. BBR Partners LLC boosted its position in Altimmune by 4.5% during the 2nd quarter. BBR Partners LLC now owns 374,784 shares of the company's stock worth $2,492,000 after purchasing an additional 16,271 shares during the period. SG Americas Securities LLC increased its holdings in Altimmune by 542.8% in the 2nd quarter. SG Americas Securities LLC now owns 254,571 shares of the company's stock valued at $1,693,000 after purchasing an additional 214,968 shares in the last quarter. Bank of New York Mellon Corp raised its position in Altimmune by 28.6% in the second quarter. Bank of New York Mellon Corp now owns 243,808 shares of the company's stock valued at $1,621,000 after purchasing an additional 54,154 shares during the period. Finally, Exchange Traded Concepts LLC lifted its stake in shares of Altimmune by 74.4% during the third quarter. Exchange Traded Concepts LLC now owns 216,761 shares of the company's stock worth $1,331,000 after purchasing an additional 92,498 shares in the last quarter. 78.05% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ALT has been the subject of a number of recent research reports. Evercore ISI upgraded Altimmune to a "strong-buy" rating in a research note on Friday, August 9th. UBS Group assumed coverage on shares of Altimmune in a research note on Tuesday, November 12th. They set a "buy" rating and a $26.00 price objective on the stock. HC Wainwright reissued a "buy" rating and set a $12.00 target price on shares of Altimmune in a research report on Thursday, November 14th. Finally, B. Riley reaffirmed a "buy" rating and set a $20.00 price target on shares of Altimmune in a report on Monday, August 12th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Altimmune currently has an average rating of "Moderate Buy" and an average price target of $20.00.

Altimmune Price Performance

Shares of NASDAQ:ALT traded down $0.16 during midday trading on Friday, reaching $8.57. The company had a trading volume of 1,145,004 shares, compared to its average volume of 4,207,724. The stock has a market capitalization of $609.54 million, a P/E ratio of -5.53 and a beta of 0.09. The stock's fifty day moving average price is $7.21 and its 200-day moving average price is $6.98. Altimmune, Inc. has a one year low of $3.16 and a one year high of $14.84.

Altimmune (NASDAQ:ALT - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.03. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The company had revenue of $0.01 million during the quarter. During the same period in the previous year, the firm posted ($0.39) EPS. As a group, sell-side analysts forecast that Altimmune, Inc. will post -1.36 earnings per share for the current year.

Altimmune Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.